吴诚中,男,1952年出生,台湾, 台中榮民總醫院外科部/一般外科 主治醫師。
学术成就:
1.Successful management of latrogenic aortoduodenal fistula by intraaortic endovascular stent-graft and duodenal diversion. Yu,-C-C; Lee,-W-L; Ho,-W-M; Wu,-C-C; Liu,-T-J; P'eng,-F-K. Hepatogastroenterology. 2007 Mar; 54(74): 431-3
2.The influence of high serum testosterone levels on the long-term prognosis in male patients undergoing hepatectomy for early stage hepatocellular carcinoma without vascular invasion. Lin,-M-C; Wu,-C-C; Cheng,-S-B; Liu,-T-J; P'eng,-F-K. World-J-Surg. 2007 Jul; 31(7): 1469-73
3.Papillary carcinoma of thyroid with breast metastasis: report of a case. Huang, -W-H, Lee, -F-Y, Wu, -C-C, Wang John. Formos J Surg 2007; 40:255-259
4.Metastasis in para-aortic lymph nodes in patients with advanced gastric cancer, treated with extended lymphadenectomy. Yonemura, Y; Wu, CC; Fukushima, N, et al. HEPATO-GASTROENTEROLOGY Volume: 54 Issue: 74 Pages: 634-638 Published: MAR 2007
5.Effects of hepatitis B virus X protein (HBx) on cell-growth inhibition in a CCL13-HBx stable cell line. Kuo C-Y, Wang J-C, Wu C-C., Hsu S-L., Hwang G-Y. Intervirology 2008; 51:26-32.
6.HBx inhibits the growth of CCL13-HBX-stable cell via the GSK-3B/B-Catenin Cascade. Kuo C-Y., Wu C-C., Hsu S-L., Hwang G-Y. Intervirology 2008; 51:130-136.
7.Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer. Yonemura,-Y; Wu,-C-C; Fukushima,-N; Honda,-I; Bandou,-E; Kawamura,-T; Kamata,-T; Kim,-B-S; Matsuki,-N; Sawa,-T; Noh,-S-H. East-Asia-Surgical-Oncology-Group. Int-J-Clin-Oncol. 2008 Apr; 13(2): 132-7
8.Hepatocellular carcinoma arising from ectopic liver: report of a case. Peng -C-M., Chen, -J-B., Wu, -C-C., Wang John. Forms J Surg 2008; 41:163-167.
9.Second and third hepatectomies for recurrent hepatocellular carcinoma are justified. Wu C.-C., Cheng S.-B., Yeh D.-C., J. Wang, P'eng F.-K.. BR J Surg 2009; 96(9): 1049—57.
10.Eosinophilic cholangitis with obstructive jaundice mimicking bile duct carcinoma. Chen WH, Yu CC, Wu CC, Jan YJ. J Hepatobiliary Pancreat Surg. 2009;16(2):242-5.
11.Combined Primary Neuroendocrine Carcinoma and Hepatocellular Carcinoma of the Liver. Yang CS, Wen MC, Jan YJe, Wang John, Wu CC. J Chin Med Assoc 2009; 72: 430-433
12.Liver resection for hepatocellular carcinoma in cirrhotic patients with gastroesophageal varices. Wu CC, Cheng SB, Yeh HZ, et al. J Gastroenterology And Hepatology 24: A207-A207, Suppl. 1 Published: OCT 2009
13.Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage. Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW et al. J Hepatology 50(5): 958-968. 2009
14.Factors related to clinical hypothyroid severity in thyroid cancer patients after thyroid hormone withdrawal. Huang S.C., Wu V.C., Lin S.Y., Wayne H.H. Sheu, Song Y.M., Lin Y.H., Wu C.C., Chang W.D. Thyroid 2009 Jan. 19(1): 13-20.
15.Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage. Liu, CJ, Lee, PHg, Lin, DY, Wu, CC, Jeng, LB, Lin, PW, Mok, KT, Lee, WC, Yeh, HZ, Ho, MC, Yang, SS, Lee, CC, Yu, MC, Hu, RH, Peng, CY, Lai, KL, Chang, Stanley SC , Chen, PJ. J Hepatology 50(5): 958-968, 2009
16.Somatic mutations of mitochondrial genome in hepatocellular carcinoma. Yin PH, Wu CC, Lin JC, Chi CW, Wei YH and Lee HC. Mitochondrion 10(2), March 2010, Pages 174-182
17.Synchronous renal cell carcinoma and clear cell hepatocellular carcinoma mimicking metastatic disease. Hou, TC, Wu, CC, Yang, CR, Wang, John. Pathology Research And Practice 206(5): 342-345, 2010